Herman W. Powery II, PharmD, BCOP

Articles by Herman W. Powery II, PharmD, BCOP

Current Drug Pathways in Non–Small Cell Lung Cancer

December 13th 2021

Advancements in genomic and mutational analysis show that up to 60% of adenocarcinomas and up to 50% to 80% of squamous cell carcinomas (SCC) have a known oncogenic driver mutation.

Latest Updated Articles

Trending on Pharmacy Times

Dato-DXd Doubles Response Rates and Extends Survival in First-Line Metastatic TNBC

Emerging Biomarkers Open New Frontiers in Lung Cancer Therapy

Final EMBARK Data Show “Almost Unprecedented” Reduction in Risk of Death With Enzalutamide Plus ADT in Biochemically Recurrent Prostate Cancer

Weekly Paclitaxel May Hold the Key to Pembrolizumab’s Success in Platinum-Resistance Ovarian Cancer

Targeted α-Particle Radioligand Therapy Shows Promising Activity, Low Toxicity in SSTR2-Positive Neuroendocrine Tumors